Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis.

[1]  Y. Soini,et al.  Progression of human aortic valve stenosis is associated with tenascin-C expression. , 2002, Journal of the American College of Cardiology.

[2]  C. Graham,et al.  Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. , 2001, Experimental cell research.

[3]  R. Levy,et al.  Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. , 2001, The American journal of pathology.

[4]  Y. Soini,et al.  Expression of MMP2, MMP9, MT1‐MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart , 2001, The Journal of pathology.

[5]  E. Ohlstein,et al.  Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. , 2001, Life sciences.

[6]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[7]  J. Shirani,et al.  Matrix metalloproteinase expression in nonrheumatic aortic stenosis. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[8]  R. Levy,et al.  Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. , 2000, The American journal of pathology.

[9]  H. J. Kim,et al.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. , 2000, The Biochemical journal.

[10]  R. Gibbons,et al.  ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). , 1998, The Journal of heart valve disease.

[11]  D. Mann,et al.  Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. , 1998, Circulation.

[12]  P. Libby,et al.  Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. , 1997, Circulation.

[13]  B. Warren,et al.  Calcification of the aortic valve: Its progression and grading , 1997, Pathology.

[14]  W. Stetler-Stevenson,et al.  Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. , 1997, Analytical biochemistry.

[15]  L. Chow,et al.  Structure of the human type IV collagenase gene. , 1990, The Journal of biological chemistry.

[16]  L. Liotta,et al.  Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.

[17]  A. Eisen,et al.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. , 1989, The Journal of biological chemistry.

[18]  R. Mecham,et al.  Characterization of biologically active domains on elastin: identification of a monoclonal antibody to a cell recognition site. , 1986, Biochemistry.

[19]  R. Thompson,et al.  Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Dowdle,et al.  Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. , 1980, Analytical biochemistry.

[21]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[22]  L. Blackford,et al.  CALCIFICATION OF THE AORTIC VALVE , 1936 .